HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-1329 | Pharmaceuticals and Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
HIV Integrase Strand Transfer Inhibitors (INSTI) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET
7.1 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA HIV INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Adcock Ingram Limited
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Affine Formulations Limited
16.3 Aurobindo Pharma
16.4 Biocon Limited
16.5 Bristol-Myers Squibb
16.6 Cipla
16.7 Emcure Pharmaceuticals
16.8 Flamingo Pharmaceuticals Limited
16.9 Gilead Sciences
16.10 Hetero Drugs
16.11 IPCA Laboratories
16.12 Janssen Pharmaceutica (Johnson & Johnson)
16.13 LAURUS Labs
16.14 Medisist Pharma
16.15 Merck
16.16 Mylan
16.17 Ranbaxy Pharmaceuticals
16.18 Shanghai Desano Pharmaceuticals
16.19 ViiV Healthcare (GSK)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeRaltegravir
Elvitegravir Combination Drugs
Dolutegravir and Its Combination Drug
Bictegravir Combination Drug
Cabotegravir
By Application
Hospital
Clinic
Drug Center
Companies
Adcock Ingram Limited
Affine Formulations Limited
Aurobindo Pharma
Biocon Limited
Bristol-Myers Squibb
Cipla
Emcure Pharmaceuticals
Flamingo Pharmaceuticals Limited
Gilead Sciences
Hetero Drugs
IPCA Laboratories
Janssen Pharmaceutica (Johnson & Johnson)
LAURUS Labs
Medisist Pharma
Merck
Mylan
Ranbaxy Pharmaceuticals
Shanghai Desano Pharmaceuticals
ViiV Healthcare (GSK)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.